MedPath

DEXTENZA

These highlights do not include all the information needed to use DEXTENZA safely and effectively. See full prescribing information for DEXTENZA. DEXTENZA (dexamethasone ophthalmic insert) 0.4 mg, for intracanalicular useInitial U.S. Approval: 1958

Approved
Approval ID

7514e6b8-c33f-4fbf-8810-ef520e1eb4bd

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Oct 19, 2021

Manufacturers
FDA

Ocular Therapeutix, Inc.

DUNS: 063391985

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

dexamethasone

PRODUCT DETAILS

NDC Product Code70382-204
Application NumberNDA208742
Marketing CategoryC73594
Route of AdministrationOPHTHALMIC, INTRACANALICULAR
Effective DateNovember 30, 2018
Generic Namedexamethasone

INGREDIENTS (6)

LYSYLLYSYLLYSINEInactive
Code: Y7F82M80K8
Classification: IACT
FLUORESCEINInactive
Code: TPY09G7XIR
Classification: IACT
SODIUM PHOSPHATE, MONOBASIC, ANHYDROUSInactive
Code: KH7I04HPUU
Classification: IACT
dexamethasoneActive
Quantity: 0.4 mg in 1 1
Code: 7S5I7G3JQL
Classification: ACTIB
POLYETHYLENE GLYCOL, UNSPECIFIEDInactive
Code: 3WJQ0SDW1A
Classification: IACT
SODIUM PHOSPHATE, DIBASIC, ANHYDROUSInactive
Code: 22ADO53M6F
Classification: IACT

Drug Labeling Information

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

LOINC: 51945-4Updated: 4/18/2025

INDICATIONS & USAGE SECTION

LOINC: 34067-9Updated: 4/18/2025

CONTRAINDICATIONS SECTION

LOINC: 34070-3Updated: 4/18/2025

WARNINGS AND PRECAUTIONS SECTION

LOINC: 43685-7Updated: 4/18/2025

ADVERSE REACTIONS SECTION

LOINC: 34084-4Updated: 4/18/2025

CLINICAL PHARMACOLOGY SECTION

LOINC: 34090-1Updated: 4/18/2025

CLINICAL STUDIES SECTION

LOINC: 34092-7Updated: 4/18/2025

DESCRIPTION SECTION

LOINC: 34089-3Updated: 4/18/2025

DOSAGE & ADMINISTRATION SECTION

LOINC: 34068-7Updated: 4/18/2025

INFORMATION FOR PATIENTS SECTION

LOINC: 34076-0Updated: 4/18/2025

RECENT MAJOR CHANGES SECTION

LOINC: 43683-2Updated: 4/18/2025

DOSAGE FORMS & STRENGTHS SECTION

LOINC: 43678-2Updated: 4/18/2025

USE IN SPECIFIC POPULATIONS SECTION

LOINC: 43684-0Updated: 4/18/2025

HOW SUPPLIED SECTION

LOINC: 34069-5Updated: 4/18/2025

NONCLINICAL TOXICOLOGY SECTION

LOINC: 43680-8Updated: 4/18/2025
© Copyright 2025. All Rights Reserved by MedPath
DEXTENZA - FDA Approval | MedPath